FDA Grants Profound Medical Corp. IDE Approval for TULSA-PRO™

TORONTO, May 19, 2016  -- Profound Medical Corp. (PRN.V), an emerging medical device company focused on prostate care, today announced that it has been granted Investigational Device Exemption (“IDE”) approval from the U.S. Food and Drug Administration (“FDA”), for a multicenter Pivotal Clinical Trial (“Pivotal Trial”). The objective of this trial is to evaluate the efficacy of the TULSA-PROTM System in patients with localized prostate cancer.
TULSA-PRO is a unique technology that combines real-time Magnetic Resonance Imaging (MRI) with transurethral robotically-driven ultrasound and closed-loop thermal feedback control providing a highly precise prostate treatment tailored to patient-specific anatomy.
“We are delighted to announce that TULSA-PRO has received IDE approval,” commented Profound CEO, Steve Plymale. “With this approval, clinicians participating in the study will be able to further validate the efficacy of this innovative technology. The commencement of this multijurisdictional Pivotal Trial is a significant milestone for Profound as it aims to establish TULSA-PRO as a minimally invasive alternative to other prostate care therapies. This study is expected to set the path to 510k regulatory approval and we look forward to working with the FDA to bring this unique technology to clinicians and patients across the United States.”
Read more: Profound Medical Corp ( PRN )

Cesca Therapeutics Announces Publication of a Case Report on Use of Its Technology for Treatment of Acute Myocardial Infarction

Data highlights promising results obtained from the AMIRST pilot study.
RANCHO CORDOVA, Calif., May 19, 2016  -- Cesca Therapeutics Inc. (KOOL), an autologous cell-based regenerative medicine company, today announced publication of data from a pilot study utilizing the company’s innovative technology for treatment of Acute Myocardial Infarction. The report was published in the “International Journal of the Cardiovascular Academy”, currently online*.
Results from the single-patient study titled, “Autologous bone marrow concentrate enriched in progenitor cells - an adjuvant in the treatment of acute myocardial infarction” were obtained using Cesca’s integrated point-of-care technology, Acute Myocardial Infarction Rapid Stem cell Therapy (AMIRST).
Read more: Cesca Therapeutics Inc ( KOOL )

Symmetry Surgical Inc. to be acquired by RoundTable Healthcare Partners for $13.10 per share in cash

Transaction values Symmetry Surgical Inc. at approximately $140.3 million
Pre-announces financial results for the first quarter ended April 2, 2016
Conference Call to Discuss Transaction Scheduled for 8:00 am ET on Tuesday, May 3, 2016
NASHVILLE, Tenn., May 02, 2016 - Symmetry Surgical Inc. (SSRG) (“Symmetry” or the “Company”), today announced that it has entered into a definitive agreement to be acquired with an equity value of $140.3 million by an affiliate of RoundTable Healthcare Partners (“RoundTable”), an operating-oriented private equity firm focused exclusively on the healthcare industry.  Under the terms of the agreement, Symmetry shareholders will receive $13.10 in cash for each share of Symmetry common stock, representing a 26% premium to the closing price of the Company’s common stock on April 29, 2016.  The agreement was unanimously approved by Symmetry’s Board of Directors.
Read more: Symmetry Surgical Inc ( SSRG )

Mazor Robotics Signs Strategic Commercial and Investment Agreements With Medtronic, a Global Leader in Spine Technologies and Solutions

CAESAREA, Israel -- Mazor Robotics Ltd. (TASE: MZOR; NASDAQGM: MZOR), a leading developer of innovative bone mounted surgical robotic guidance systems, today entered into two strategic agreements with Medtronic plc (MDT). One agreement is a two-stage, multi-faceted, commercial agreement for co-promotion, co-development and, upon meeting certain milestones, potential global distribution of certain Mazor products. The second agreement is for an equity investment by Medtronic in Mazor.
Commercial Agreement
The commercial agreement has an initial U.S.-based co-promotion phase. If both organizations achieve their respective milestones by the end of 2017, then the companies will enter the second phase of the agreement, in which Medtronic will assume exclusive global sales and distribution rights for Mazor’s future spine products. 
Read more: Mazor Robotics Ltd ( MZOR )

Dehaier Medical Receives US$20 Million Strategic Investment from Liaison Interactive

BEIJING, April 28, 2016 -- Dehaier Medical Systems Ltd. (DHRM) ("Dehaier Medical" or the "Company"), which develops, markets and sells medical devices and wearable sleep respiratory products in China and international markets, today announced that it entered into a definitive securities purchase agreement (the "Agreement") with Hangzhou Liaison Interactive Information Technology Co. Ltd. ("Liaison Interactive" or the "Purchaser"), a publicly listed company on the Shenzhen Stock Exchange (Trading Ticker: 002280) pursuant to which the Liaison Interactive has agreed to purchase 11,111,111 restricted common shares of the Company (the "Shares") for an aggregate of US$20,000,000 (the "Purchase Price"). The Purchase Price is US$1.80 per share, which represents a 35% premium to Dehaier Medical's closing price of $1.33 on April 27, 2016.
In consideration of the payment by the Buyer of the Purchase Price, the Buyer and its designees will also receive warrants to purchase 1,000,000 restricted common shares of the Company at a purchase price of US$2.20 per share (the "Warrants").  The Warrants are exercisable by the Buyer or its designees in whole or in part and are exercisable at any time after the Closing.
Read more: Dehaier Medical Systems Ltd ( DHRM )

Videos / Webinars

View all videos

Pepperstone | Metatrader 4 Forex Broker